As of August 24, 2018, Putnam Capital Opportunities Fund merged into Putnam Small Cap Growth Fund.

Small Cap Growth Fund (Class Y)  (PSYGX)

Seeking to capitalize on growing small companies

Highlights

Objective

The fund seeks capital appreciation.

Strategy and process

  • Small companies: Often overlooked by Wall Street analysts, the stocks of small companies can represent attractive opportunities.
  • A focus on growth: Small companies tend to be flexible and innovative, and can often expand their earnings at faster rates than larger companies.
  • A disciplined process: The portfolio manager uses a disciplined bottom-up fundamental investment process that focuses on quality and growth.

Fund price

Yesterday’s close 52-week high 52-week low
Net asset value $42.43
-2.03% | $-0.88
$48.42
09/11/18
$37.29
11/15/17
Historical fund price

Fund facts as of 10/31/18

Total net assets
$435.52M
Turnover (fiscal year end)
68%
Dividend frequency
Annually
Number of holdings
79
Fiscal year-end
June
CUSIP / Fund code
746763499 / 1852
Inception date
11/03/03
Class Y  
Category
Growth
Open to new investors
Ticker
PSYGX

Management team

Portfolio Manager



Performance

  • Total return (%) as of 09/30/18

  • Annual performance as of 09/30/18

Annualized Total return (%) as of 09/30/18

Annualized performance 1 yr. 3 yrs. 5 yrs. 10 yrs.
Before sales charge 31.20% 19.18% 12.35% 12.01%
After sales charge N/A N/A N/A N/A
Russell 2000 Growth Index 21.06% 17.98% 12.14% 12.65%

Current performance may be lower or higher than the quoted past performance, which cannot guarantee future results. Share price, principal value, and return will vary, and you may have a gain or loss when you sell your shares. Performance assumes reinvestment of distributions and does not account for taxes. Returns before sales charge do not reflect the current maximum sales charges as indicated below. Had the sales charge been reflected, returns would be lower. Returns at public offering price (after sales charge) for class A and class M shares reflect the current maximum initial sales charges of 5.75% and 3.50% for equity funds and Putnam Multi-Asset Absolute Return Fund, and 4.00% and 3.25% for income funds (2.25% and 0.75% for Putnam Short Duration Bond Fund and 1.00% and 0.75% for Putnam Floating Rate Income Fund, Putnam Fixed Income Absolute Return Fund, and Putnam Short-Term Municipal Income Fund), respectively. Class B share returns reflect the applicable contingent deferred sales charge (CDSC), which is 5% in the first year, declining to 1% in the sixth year, and is eliminated thereafter (except for Putnam Floating Rate Income Fund, Putnam Short Duration Bond Fund, Putnam Fixed Income Absolute Return Fund, and Putnam Short-Term Municipal Income Fund, which is 1% in the first year, declining to 0.5% in the second year, and is eliminated thereafter). Class C shares reflect a 1% CDSC the first year that is eliminated thereafter. Performance for class B, C, M, N, R, T1, and Y shares prior to their inception is derived from the historical performance of class A shares, adjusted for the applicable sales charge (or CDSC) and, except for class Y shares, the higher operating expenses for such shares (with the exception of Putnam Tax-Free High Yield Fund and Putnam AMT-Free Municipal Fund, which are based on the historical performance of class B shares). Returns at public offering price (after sales charge) for class N shares reflect the current maximum initial sales charge of 1.50%. Class R5/R6 shares, available to qualified employee-benefit plans only, are sold without an initial sales charge and have no CDSC. Class Y shares are generally only available for corporate and institutional clients and have no initial sales charge. Performance for Class R5/R6 shares before their inception are derived from the historical performance of class Y shares, which have not been adjusted for the lower expenses; had they, returns would have been higher. Class A, M, and T1 shares of Putnam money market funds have no initial sales charge. For a portion of the period, some funds had expenses limitations or had been sold on a limited basis with limited assets and expenses, without which returns would be lower.

Performance snapshot

  Before sales charge After sales charge
1 mt. as of 10/31/18 -12.27 % -
YTD as of 11/09/18 10.36 % -

Risk-adjusted performance as of 09/30/18

Alpha (3 yrs.) 0.47
Sharpe ratio (3 yrs.) 1.30
Treynor ratio (3 yrs.) 17.67
Information ratio (3 yrs.) 0.37

Volatility as of 09/30/18

Standard deviation (3 yrs.) 14.13%
Beta 1.04
R-squared 0.95

Capture ratio as of 09/30/18

Up-market (3 yrs.) 104.00
Down-market (3 yrs.) 100.61

Lipper rankings as of 09/30/18

Time period Rank/Funds in category Percentile ranking
1 yr. 147/556 27%
3 yrs. 190/484 40%
5 yrs. 183/436 42%
10 yrs. 226/329 69%
Lipper category: Small-Cap Growth Funds

Morningstar Ratings as of 09/30/18

Time period Funds in category Morningstar Rating
Overall 606
3 yrs. 606
5 yrs. 532
10 yrs. 404
Morningstar category: Small Growth

Distributions

Record/Ex dividend date 08/22/18
Payable date 08/24/18
Income --
Extra income --
Short-term cap. gain --
Long-term cap. gain $0.68

Lipper rankings are based on total return without sales charge relative to all share classes of funds with similar objectives as determined by Lipper. Past performance is not indicative of future results.

The Morningstar RatingTM for funds, or "star rating", is calculated for managed products (including mutual funds, variable annuity and variable life subaccounts, exchange-traded funds, closed-end funds, and separate accounts) with at least a three-year history. Exchange-traded funds and open-ended mutual funds are considered a single population for comparative purposes. It is calculated based on a Morningstar Risk-Adjusted Return measure that accounts for variation in a managed product's monthly excess performance, placing more emphasis on downward variations and rewarding consistent performance. The top 10% of products in each product category receive 5 stars, the next 22.5% receive 4 stars, the next 35% receive 3 stars, the next 22.5% receive 2 stars, and the bottom 10% receive 1 star. The Overall Morningstar Rating for a managed product is derived from a weighted average of the performance figures associated with its three-, five-, and 10-year (if applicable) Morningstar Rating metrics. The weights are: 100% three-year rating for 36-59 months of total returns, 60% five-year rating/40% three-year rating for 60-119 months of total returns, and 50% 10-year rating/30% five-year rating/20% three-year rating for 120 or more months of total returns. While the 10-year overall star rating formula seems to give the most weight to the 10-year period, the most recent three-year period actually has the greatest impact because it is included in all three rating periods.

The up-market capture ratio is used to evaluate how well an investment manager performed relative to an index during periods when that index has risen. The ratio is calculated by dividing the manager’s returns by the returns of the index during the up-market, and multiplying that factor by 100. The down-market capture ratio is used to evaluate how well an investment manager performed relative to an index during periods when that index has dropped. The ratio is calculated by dividing the manager’s returns by the returns of the index during the down-market and multiplying that factor by 100.


Compare

See how this fund stacks up against its peers with FundVisualizer®

— or —

New to FundVisualizer? Watch tutorials on how to get started.

For more tutorials, please visit Advisor Tech Tips

** FundVisualizer comparison based on Putnam fund versus the largest fund in its Morningstar category.


Holdings

Top 10 holdings as of 09/30/18

Five Below 3.38%
Wingstop 2.69%
Realpage 2.47%
Ligand Pharmaceuticals 2.44%
Trex 2.40%
Merit Medical Systems 2.23%
John Bean Technologies Corp 2.19%
Bright Horizons Family Solutions 2.17%
Mercury Systems 2.11%
Heico Corp 1.96%
Top 10 holdings, percent of portfolio 24.04%

Full portfolio holdings as of 09/30/18

FIVE BELOW 3.38%
WINGSTOP INC 2.69%
REALPAGE INC 2.47%
LIGAND PHARMACEUTICALS 2.44%
TREX COMPANY INC 2.40%
MERIT MEDICAL SYSTEMS INC 2.23%
JOHN BEAN TECHNOLOGIES CORP 2.19%
BRIGHT HORIZONS FAMILY SOLUT 2.17%
MERCURY SYSTEMS INC 2.11%
HEICO CORP 1.96%
GRAND CANYON EDUCATION INC 1.94%
SITEONE LANDSCAPE SUPPLY INC 1.84%
HAMILTON LANE INC-CLASS A 1.81%
EMERGENT BIOSOLUTIONS INC 1.77%
EVERCORE INC - A 1.75%
QUIDEL CORP 1.75%
NOVANTA INC 1.62%
EVERBRIDGE INC 1.60%
FERRO CORP 1.57%
FOCUS FINANCIAL PARTNERS-A 1.56%
CABLE ONE INC 1.55%
LITTELFUSE INC 1.55%
ENVESTNET INC 1.54%
AT HOME GROUP INC 1.45%
INSULET CORP 1.41%
INTEGRATED DEVICE TECH INC 1.35%
QAD INC-A 1.34%
LIVE NATION ENTERTAINMENT IN 1.27%
CONMED CORP 1.21%
PAYLOCITY HOLDING CORP 1.21%
TABULA RASA HEALTHCARE INC 1.21%
ORION ENGINEERED CARBONS SA 1.20%
TACTILE SYSTEMS TECHNOLOGY I 1.18%
HEALTHEQUITY INC 1.12%
KINSALE CAPITAL GROUP INC 1.11%
RINGCENTRAL INC-CLASS A 1.11%
PLANET FITNESS INC - CL A 1.09%
PROTO LABS INC 1.09%
SAIA INC 1.04%
MGP INGREDIENTS INC 1.01%
EVO PAYMENTS INC-CLASS A 1.00%
SAREPTA THERAPEUTICS INC 0.98%
HARSCO CORP 0.96%
NATIONAL VISION HOLDINGS INC 0.96%
H AND E EQUIPMENT SERVICES INC 0.94%
REPLIGEN CORP 0.94%
2U INC 0.93%
ALTERYX INC - CLASS A 0.93%
CADENCE BANCORP 0.88%
Q2 HOLDINGS INC 0.87%
BROOKS AUTOMATION INC 0.86%
BWX TECHNOLOGIES INC 0.85%
PATRICK INDUSTRIES INC 0.84%
BRIGHTVIEW HOLDINGS INC 0.82%
PENUMBRA INC 0.82%
PROS HOLDINGS INC 0.82%
TELADOC HEALTH INC 0.82%
CENTRAL GARDEN AND PET CO-A 0.81%
BLACKLINE INC 0.77%
PROOFPOINT INC 0.76%
AXOGEN INC 0.75%
EXACT SCIENCES CORP 0.75%
SUMMIT MATERIALS INC -CL A 0.73%
ENTEGRIS INC 0.69%
MIMECAST LTD 0.69%
ACCELERON PHARMA INC 0.68%
J2 GLOBAL INC 0.68%
CHEGG INC 0.66%
TALEND SA - ADR 0.66%
CODEXIS INC 0.57%
ASCENDIS PHARMA A/S - ADR 0.56%
ARRAY BIOPHARMA INC 0.54%
SUPERNUS PHARMACEUTICALS INC 0.52%
AERIE PHARMACEUTICALS INC 0.51%
WORLD WRESTLING ENTERTAIN-A 0.51%
MIRATI THERAPEUTICS INC 0.47%
AMICUS THERAPEUTICS INC 0.46%
LOXO ONCOLOGY INC 0.45%
IRONWOOD PHARMACEUTICALS INC 0.41%
GLOBAL BLOOD THERAPEUTICS IN 0.39%
ATARA BIOTHERAPEUTICS INC 0.38%
MEDICINES COMPANY 0.32%
SPARK THERAPEUTICS INC 0.31%
VERICEL CORP 0.31%
SVMK INC 0.14%

Prior top 10 holdings

Top 10 holdings as of 09/30/18
Five Below
Wingstop
Realpage
Ligand Pharmaceuticals
Trex
Merit Medical Systems
John Bean Technologies Corp
Bright Horizons Family Solutions
Mercury Systems
Heico Corp
Holdings represent 24.04% of portfolio
Top 10 holdings as of 08/31/18
Trex
Wingstop
John Bean Technologies Corp
Realpage
Ligand Pharmaceuticals
Bright Horizons Family Solutions
Siteone Landscape Supply
Hamilton Lane
Heico Corp
Merit Medical Systems
Holdings represent 20.47% of portfolio
Top 10 holdings as of 07/31/18
Five Below
Trex
Siteone Landscape Supply
Realpage
John Bean Technologies Corp
Hamilton Lane
Ligand Pharmaceuticals
Merit Medical Systems
Wingstop
Bright Horizons Family Solutions
Holdings represent 23.18% of portfolio
Top 10 holdings as of 06/30/18
Five Below
Realpage
Wingstop
Siteone Landscape Supply
Hamilton Lane
Trex
Ligand Pharmaceuticals
Bright Horizons Family Solutions
Grand Canyon Education
Merit Medical Systems
Holdings represent 22.43% of portfolio

Portfolio composition as of 09/30/18

Common stock 97.03%
Cash and net other assets 2.97%

Equity statistics as of 09/30/18

Median market cap $2.77B
Weighted average market cap $3.95B
Price to book 7.03
Price to earnings 39.61

Fund characteristics will vary over time.

Due to rounding, percentages may not equal 100%.

Consider these risks before investing: Investments in small and/or midsize companies increase the risk of greater price fluctuations. Growth stocks may be more susceptible to earnings disappointments, and the market may not favor growth-style investing. Stock prices may fall or fail to rise over time for a variety of reasons, including general financial market conditions, changing market perceptions, changes in government intervention in the financial markets, and factors related to a specific issuer or industry. From time to time, the fund may invest a significant portion of its assets in companies in one or more related industries or sectors, which would make the fund more vulnerable to adverse developments affecting those industries or sectors. You can lose money by investing in the fund.

Top industry sectors as of 09/30/18

Health care 26.27%
Information technology 23.64%
Industrials 17.02%
Consumer discretionary 14.34%
Financials 7.11%
Materials 3.50%
Communication services 3.33%
Cash and net other assets 2.97%
Consumer staples 1.82%

The unclassified sector (where applicable) includes exchange traded funds and other securities not able to be classified by sector.

Sectors will vary over time.


Expenses

Expense ratio

Class A Class B Class C Class M Class R Class R6 Class Y
Total expense ratio 1.20% 1.95% 1.95% 1.70% 1.45% 0.77% 0.95%
What you pay 1.20% 1.95% 1.95% 1.70% 1.45% 0.77% 0.95%

Sales charge

 Breakpoint Class A Class B Class C Class M Class R Class R6 Class Y
$0-$49,999 5.75% / 5.00% 0.00% / 4.00% 0.00% / 1.00% 3.50% / 3.00% -- -- --
$50,000-$99,999 4.50% / 3.75% 0.00% / 4.00% 0.00% / 1.00% 2.50% / 2.00% -- -- --
$100,000-$249,999 3.50% / 2.75% -- 0.00% / 1.00% 1.50% / 1.00% -- -- --
$250,000-$499,999 2.50% / 2.00% -- 0.00% / 1.00% 1.00% / 1.00% -- -- --
$500,000-$999,999 2.00% / 1.75% -- 0.00% / 1.00% 1.00% / 1.00% -- -- --
$1M-$4M 0.00% / 1.00% -- -- -- -- -- --
$4M-$50M 0.00% / 0.50% -- -- -- -- -- --
$50M+ 0.00% / 0.25% -- -- -- -- -- --

CDSC

  Class A (sales for $1,000,000+) Class B Class C Class M Class R Class R6 Class Y
0 to 9 mts. 1.00% 5.00% 1.00% -- -- -- --
9 to 12 mts. 1.00% 5.00% 1.00% -- -- -- --
2 yrs. 0.00% 4.00% 0.00% -- -- -- --
3 yrs. 0.00% 3.00% 0.00% -- -- -- --
4 yrs. 0.00% 3.00% 0.00% -- -- -- --
5 yrs. 0.00% 2.00% 0.00% -- -- -- --
6 yrs. 0.00% 1.00% 0.00% -- -- -- --
7+ yrs. 0.00% 0.00% 0.00% -- -- -- --

Trail commissions

  Class A Class B Class C Class M Class R Class R6 Class Y
  0.25% 0.25% 1.00% 0.65% 0.50% 0.00% 0.00%
  NA NA NA NA NA NA NA
  NA NA NA NA NA NA NA

For sales and trail commission information on purchases over $1 million and participant-directed qualified retirement plans, see a Putnam fund prospectus and the statement of additional information.

The Russell 2000 Growth Index is an unmanaged index of those companies in the small-cap Russell 2000 Index chosen for their growth orientation. You cannot invest directly in an index.

Consider these risks before investing: Investments in small and/or midsize companies increase the risk of greater price fluctuations. Growth stocks may be more susceptible to earnings disappointments, and the market may not favor growth-style investing. Stock prices may fall or fail to rise over time for a variety of reasons, including general financial market conditions, changing market perceptions, changes in government intervention in the financial markets, and factors related to a specific issuer or industry. From time to time, the fund may invest a significant portion of its assets in companies in one or more related industries or sectors, which would make the fund more vulnerable to adverse developments affecting those industries or sectors. You can lose money by investing in the fund.